Hussein Tawbi
M.D. Anderson Cancer Center · University of Pittsburgh Medical Center / Hillman Cancer Center · University of Pittsburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hussein Tawbi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:48 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06683755 · Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)M.D. Anderson Cancer Center · recruiting · Melanoma · principal investigator
- Ph2NCT05704647 · Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesM.D. Anderson Cancer Center · recruiting · Melanoma (Skin) · principal investigator
- Ph1/Ph2NCT03131908 · Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossM.D. Anderson Cancer Center · completed · Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma · principal investigator
- Ph2NCT02816021 · Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · completed · Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma · principal investigator
- Ph1NCT02357732 · Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibUniversity of Pittsburgh · withdrawn · Metastatic Melanoma · principal investigator
- Ph2NCT02301039 · SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasSarcoma Alliance for Research through Collaboration · completed · Soft Tissue Sarcoma, Bone Sarcoma · principal investigator
- N/ANCT01136824 · Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor BurdenUniversity of Pittsburgh · completed · Soft Tissue Sarcoma · principal investigator
- Ph1/Ph2NCT00715793 · Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic MelanomaHussein Tawbi · completed · Malignant Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 018)P30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2015 to 2018 · $8,614 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:48 UTC. The ranking covers the 200 most relevant of 58 PubMed records, and a shared surname and initials can bring in a namesake. All 58 on PubMed
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med · 20221,652 citationsRCR 113.5
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol · 20171,229 citationsRCR 42.1
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.Lancet Oncol · 2012734 citationsRCR 19.2
- 715 citationsRCR 21.5
- 660 citationsRCR 23.6
- 297 citationsRCR 17.4
- 296 citationsRCR 14.5
- 261 citationsRCR 8.4
- 250 citationsRCR 7.7